Outcomes of extended infusion piperacillin/tazobactam for documented Gram-negative infections

Diagnostic Microbiology and Infectious Disease

Volumn 64, Issue 2, 2009, Pages 236-240

  Patel, Gita Wasan ^a   Patel, Nimish ^b   Lat, Asma ^a   Trombley, Kristen ^b   Enbawe, Sam ^b   Manor, Kelli ^d   Smith, Raymond ^d   Lodise Jr , Thomas P ^b,c  

^a Medical Center of Plano   (United States)

^b ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^c ORDWAY RESEARCH INSTITUTE   (United States)

^d STRATTON VA MEDICAL CENTER   (United States)

Author keywords

Extended infusion; Outcomes; Piperacillin tazobactam

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

AGED; ARTICLE; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG DOSE REGIMEN; DRUG INTERMITTENT THERAPY; FEMALE; GRAM NEGATIVE INFECTION; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; FEMALE; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; INFUSIONS, INTRAVENOUS; LENGTH OF STAY; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PENICILLANIC ACID; PIPERACILLIN; TREATMENT OUTCOME;

EID: 66449083294     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2009.03.002     Document Type: Article

References (13)

1. Cockcroft D.W., and Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron 16 (1976) 31-41
2. Craig W.A. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin. Infect. Dis. 26 (1998) 1-10 (quiz 11-2)
3. Craig W.A., and Ebert S.C. Continuous infusion of beta-lactam antibiotics. Antimicrob. Agents Chemother. 36 (1992) 2577-2583
4. Garner J.S., Jarvis W.R., Emori T.G., Horan T.C., and Hughes J.M. CDC definitions for nosocomial infections, 1988. Am. J. Infect. Control. 16 (1988) 128-140
5. Grant E., Nicolau D.P., Nightingale C.H., and Quintiliani R. Continuous infusion of beta-lactam antibiotics. Conn. Med. 63 (1999) 275-277
6. Knaus W.A., Draper E.A., Wagner D.P., and Zimmerman J.E. APACHE II: a severity of disease classification system. Crit. Care. Med. 13 (1985) 818-829
7. Lodise T.P., Lomaestro B., Rodvold K.A., Danziger L.H., and Drusano G.L. Pharmacodynamic profiling of piperacillin in the presence of tazobactam in patients through the use of population pharmacokinetic models and Monte Carlo simulation. Antimicrob. Agents Chemother. 48 (2004) 4718-4724
8. Lodise T.P., Lomaestro B.M., and Drusano G.L. Application of antimicrobial pharmacodynamic concepts into clinical practice: focus on beta-lactam antibiotics: insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy 26 (2006) 1320-1332
9. Lodise T.P., Lomaestro B., and Drusano G.L. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy. Clin. Infect. Dis. 44 (2007) 357-363
10. Lomaestro B. Pharmacodynamic evaluation of extending the infusion time of piperacillin/tazobactam doses using Monte Carlo analysis. Program and abstracts of the 41st interscience conference on antimicrobial agents and chemotherapy. Washington, DC (2001)
11. McGregor J.C., Rich S.E., Harris A.D., Perencevich E.N., Osih R., Lodise T.P., Miller R.R., and Furuno J.P. A systematic review of the methods used to assess the association between appropriate antibiotic therapy and mortality in bacteremic patients. Clin. Infect. Dis. 45 (2007) 329-337
12. Mylotte J.M., and Tayara A. Staphylococcus aureus bacteremia: predictors of 30-day mortality in a large cohort. Clin. Infect. Dis. 31 (2000) 1170-1174
13. Shah N.P., Reddy P., Paladino J.A., McKinnon P.S., Klepser M.E., and Pashos C.L. Direct medical costs associated with using vancomycin in methicillin-resistant Staphylococcus aureus infections: an economic model. Curr. Med. Res. Opin. 20 (2004) 779-790